New Tool: PMMI ProSource
Check out our packaging and processing solutions finder, PMMI ProSource.

Spasm Medicine Goes From $40 to $34,000

Mallinckrodt will pay $100 million settlement after raising price of infantile spasm medication 85,000%.

H.P. Acthar Gel / Photo: National Library of Medicine
H.P. Acthar Gel / Photo: National Library of Medicine

A Washington Post article from January 18th detailed Mallinckrodt Pharmaceuticals’ anti-competitive behavior to preserve its monopoly on H.P. Acthar Gel, a rare-disease drug used to treat infantile spasms. In 2001, Questcor bought Acthar Gel, which once sold for $40 a vial, for $100,000 plus royalties. Questcor was then bought by Mallinckrodt in 2014 after raising the price to over $34,000 a vial. The drug brought in over $1 billion in revenue in 2015.

The 85,000% price hike wasn’t the focus of the federal and state investigations though. Rather, the FTC focused on Questcor’s acquisition of a synthetic version of Acthar to forestall future competition. Outside the U.S., Novartis was selling Synacthen, a similar medicine used to treat infantile spasms among other similar conditions. Questcor bought the U.S. rights for around $135 million.

While the drug company admits no wrongdoing, it will pay out $100 million in the settlement and has agreed to license Synacthen to a competitor approved by the FTC.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts